The APIS Team will be exhibiting at ECCMID 2023 in Copenhagen, Denmark.

APIS Assay Technologies core expertise and capabilities are contract development of molecular & immunoassay assays and their ultimate product realisation as IVD approved assays, and the related clinical compliance services (particularly for CE-IVDR).

Operating under ISO 13485 and supported by the required clinical & compliance teams, we have expertise in developing PCR (RT-qPCR, qPCR, dPCR), NGS and immunoassay (e.g. ELISA & ELONA) IVD tests. Our onsite microbiology facilities provide our clients the capabilities to develop multiplex infectious disease panels in-house.

Our new APIS SARS-CoV-2 IgG ELISA Kit is intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum. The assays’ results will aid in clinical decision making, vaccine development and booster dosing, disease prevention and research studies.

Interested in learning more? Use this link to contact us and schedule a meeting.